CORCEPT THERAPEUTICS INC Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- CORCEPT THERAPEUTICS INC payments for repurchase of common stock for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- CORCEPT THERAPEUTICS INC payments for repurchase of common stock for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- CORCEPT THERAPEUTICS INC payments for repurchase of common stock for the quarter ending 2025-12-31 was $0.00.
- CORCEPT THERAPEUTICS INC payments for repurchase of common stock for the quarter ending 2025-09-30 was $42.46M, a 262.63% increase year-over-year.
- CORCEPT THERAPEUTICS INC payments for repurchase of common stock for fiscal 2025 was $172.91M, a 1003.90% increase from fiscal 2024.
- CORCEPT THERAPEUTICS INC payments for repurchase of common stock for fiscal 2024 was $15.66M.
- CORCEPT THERAPEUTICS INC payments for repurchase of common stock for fiscal 2023 was $0.00.
- CORCEPT THERAPEUTICS INC payments for repurchase of common stock for fiscal 2022 was $0.00.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $42.46M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $0.00 10-Q · filed 2026-04-30 | $145.48M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $172.91M 10-K · filed 2026-02-24 |
| 2025-09-30 | $42.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $172.91M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $103.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $142.16M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $27.43M 10-Q · filed 2026-04-30 | $42.62M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $15.66M 10-K · filed 2026-02-24 |
| 2024-09-30 | $11.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $15.66M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $3.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $3.95M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $476.00K 10-Q · filed 2025-05-05 | $476.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-29 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-01 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | |
| 2021-09-30 | $25.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $98.16M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $29.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $72.38M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $33.54M 10-Q · filed 2022-05-05 | $43.21M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $9.67M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $9.95M 10-K · filed 2021-02-23 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $275.00K derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $275.00K derived: sum of 4 quarters · filed 2021-07-29 |
| 2020-03-31 | $275.00K 10-Q · filed 2021-05-06 | $17.70M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $30.98M 10-K · filed 2021-02-23 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-03 | $45.73M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-06-30 | $17.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $54.63M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-03-31 | $13.55M 10-Q · filed 2020-05-04 | $37.21M derived: sum of 4 quarters · filed 2021-02-23 |
| 2018-12-31 | $14.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $23.66M 10-K · filed 2021-02-23 |
| 2018-09-30 | $8.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $8.90M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $0.00 10-K · filed 2020-02-24 |
| 2016-12-31 | $0.00 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |